Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background: Despite its known insulin‐independent effects, glucagon‐like peptide‐1 (GLP‐1) role in muscle protein turnover has not been explored under fed‐state conditions or in the context of older age, when declines in insulin sensitivity and protein anabolism, as well as losses of muscle mass and function, occur. Methods: Eight older‐aged men (71 ± 1 year, mean ± SEM) were studied in a crossover trial. Baseline measures were taken over 3 hr, prior to a 3 hr postprandial insulin (~30 mIU ml−1) and glucose (7–7.5 mM) clamp, alongside I.V. infusions of octreotide and Vamin 14 (±infusions of GLP‐1). Four muscle biopsies were taken, and muscle protein turnover was quantified via incorporation of 13 C 6 phenylalanine and arteriovenous balance kinetics, using mass spectrometry. Leg macro‐ and microvascular flow was assessed via ultrasound and anabolic signalling by immunoblotting. GLP‐1 and insulin were measured by ELISA. Results: GLP‐1 augmented muscle protein synthesis (MPS; fasted: 0.058 ± 0.004% hr−1 vs. postprandial: 0.102 ± 0.005% hr−1, p < 0.01), in comparison with non‐GLP‐1 trials. Muscle protein breakdown (MPB) was reduced throughout clamp period, while net protein balance across the leg became positive in both groups. Total femoral leg blood flow was unchanged by the clamp; however, muscle microvascular blood flow (MBF) was significantly elevated in both groups, and to a significantly greater extent in the GLP‐1 group (MBF: 5 ± 2 vs. 1.9 ± 1 fold change +GLP‐1 and −GLP‐1, respectively, p < 0.01). Activation of the Akt‐mTOR signalling was similar across both trials. Conclusion: GLP‐1 infusion markedly enhanced postprandial microvascular perfusion and further stimulated muscle protein metabolism, primarily through increased MPS, during a postprandial insulin hyperaminoacidaemic clamp.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle
Cuthbertson, D., Smith, K., Babraj, J., Leese, G., Waddell, T., Atherton, P., Wackerhage, H., Taylor, P. M., & Rennie, M. J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2640fje · Cited by 1,211
Self-citationMoore, D. R., Churchward-Venne, T. A., Witard, O., Breen, L., Burd, N. A., Tipton, K. D., & Phillips, S. M. (2015) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu103 · Cited by 770
Accelerated Loss of Skeletal Muscle Strength in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Strotmeyer, E. S., Kuller, L. H., Broudeau, R., Kammerer, C., de Rekeneire, N., Harris, T. B., Schwartz, A. V., Tylavsky, F. A., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2537 · Cited by 766 · cited 1×
“…of diabetes, GLP-1 therapy is widely used in clinical practice, to improve glucose uptake and disposal, and given that muscle loss and the incidence of sarcopenia is accelerated in patients with diabetes (Park et al., 2007), GLP-1 therapies may also have a role to play in maintaining muscle mass.”
BackgroundElliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Greenhaff, P. L., Karagounis, L. G., Peirce, N., Simpson, E. J., Hazell, M., Layfield, R., Wackerhage, H., Smith, K., Atherton, P., Selby, A., et al. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90411.2008 · Cited by 495 · cited 4×
“intracellular free phenylalanine enrichment The muscle myofibrillar fraction was isolated as previously described (Atherton et al., 2010; Greenhaff et al., 2008), and L-[ring13C6]-phenylalanine incorporation into myofibrillar protein was determined by gas chromatography combustion isotope ratio…”
BackgroundMethodInfluentialSelf-citationAtherton, P. J., Etheridge, T., Watt, P. W., Wilkinson, D., Selby, A., Rankin, D., Smith, K., & Rennie, M. J. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29819 · Cited by 404 · cited 7×
“The sarcoplasmic fraction containing the intramuscular free amino acid pool was precipitated, and the supernatant was purified by cationexchange chromatography, using Dowex H+ resin and derivatised as their t-BDMS derivatives before measurement of phenylalanine enrichment by GC-MS (Atherton et al., 2010; Greenhaff et…”
BackgroundMethodSelf-citationAging is accompanied by a blunted muscle protein synthetic response to protein ingestion
Wall, B. T., Gorissen, S. H., Pennings, B., Koopman, R., Groen, B. B. L., Verdijk, L. B., & van Loon, L. J. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140903 · Cited by 352 · cited 2×
“In ageing, skeletal muscle becomes resistant to the anabolic effects of dietary EAA and insulin—termed ‘anabolic resistance’ (Cuthbertson et al., 2005; Moore et al., 2015; Wall et al., 2015).”
BackgroundNutrient signalling in the regulation of human muscle protein synthesis
Fujita, S., Dreyer, H. C., Drummond, M. J., Glynn, E. L., Cadenas, J. G., Yoshizawa, F., Volpi, E., & Rasmussen, B. B. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.134593 · Cited by 339 · cited 1×
“Since these pathways are involved in anabolic responses to nutrition driven by AA (Fujita et al., 2007) and insulin (Hillier, Long, Jahn, Wei, & Barrett, 2000), we investigated the activation of key signalling molecules in the absence and presence of GLP-1.”
BackgroundChurchward‐Venne, T. A., Burd, N. A., Mitchell, C. J., West, D. W. D., Philp, A., Marcotte, G. R., Baker, S. K., Baar, K., & Phillips, S. M. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2012.228833 · Cited by 314
Cited by
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15728 · Cited by 391
Dubin, R. L., Heymsfield, S. B., Ravussin, E., & Greenway, F. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15913 · Cited by 47
“99,100 The GLP-1RA class of drugs are proposed as a treatment for sarcopenia based on data showing that the reduction in muscle wasting by these compounds is driven by suppressing myostatin.”
Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
Yamada, S., Ogura, Y., Inoue, K., Tanabe, J., Sugaya, T., Ohata, K., Nagai, Y., Natsuki, Y., Hoshino, S., Watanabe, S., et al. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111472 · Cited by 25
Targeting skeletal muscle mitochondrial health in obesity
Pileggi, C. A., Hooks, B. G., McPherson, R., Dent, R. R. M., & Harper, M.-E. (2022) · Clinical Science · doi:10.1042/cs20210506 · Cited by 21
Rajagopal, S., Alruwaili, F., Mavratsas, V., Serna, M. K., Murthy, V. L., & Raji, M. (2023) · Cureus · doi:10.7759/cureus.51352 · Cited by 11
Metadata
- Authors
- Abdulla, H., Phillips, B. E., Wilkinson, D. J., Limb, M., Jandova, T., Bass, J. J., Rankin, D., Cegielski, J., Sayda, M., Crossland, H., Williams, J. P., Smith, K., Idris, I., & Atherton, P. J.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2020-08-03
- Volume
- 19
- Issue
- 9
- Pages
- e13202-e13202
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W3046947410
- Cited by
- 30
- References
- 19
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle. https://app.cochat.ai/papers/10.1111/acel.13202
- The paper
- Abdulla, H., Phillips, B. E., Wilkinson, D. J., Limb, M., Jandova, T., Bass, J. J., Rankin, D., Cegielski, J., Sayda, M., Crossland, H., Williams, J. P., Smith, K., Idris, I., & Atherton, P. J. (2020). Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle. Aging Cell. https://doi.org/10.1111/acel.13202
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.